has in fact identified the AGEs as a risk factor for insulin resistance independent of over-nutrition in non-obese mice [53], with such insulin resistance that occurred before changes in blood glucose levels
Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout
Employers are looking at the same drugs from a different angle
Papadopoulos, A
Berberine is not FDA-approved for weight loss or for treating medical conditions
Manu Chakravarthy, vice president at Genentech, said, Amylin helps people feel satisfied after a meal, but it doesn't make them feel like they don't want to eat at all, calling it a subtle but important difference. James List, head of internal medicine research at Pfizer, who is conducting research on amylin, said, If there is clinical differentiation, we can fill unmet gaps in the obesity drug market, adding, Even if we enter the market later, it is necessary to develop a differentiated product. Eli Lilly and Novo Nordisk, which already dominate the market, have also begun developing amylin-based therapies